Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Drug Profile

Nitric oxide inhalation - INOpulse - Bellerophon Therapeutics

Alternative Names: Inhaled nitric oxide - Bellerophon; inhaled NO; iNO- Bellerophon; Nitric oxide-INOpulse

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ikaria Holdings
  • Developer Bellerophon Therapeutics
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension
  • Phase II Pulmonary hypertension

Most Recent Events

  • 05 Sep 2017 Bellerophon completes a phase II trial in Pulmonary hypertension in Belgium
  • 05 Sep 2017 Adverse events and pharmacodynamics data from a phase II trial in Pulmonary hypertension released by Bellerophon
  • 31 Aug 2017 Bellerophon Pulse Technologies completes a phase II trial in Pulmonary hypertension in Belgium (EudraCT2016-002389-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top